IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for glaucoma and other diseases of the eye, today announced that two paper abstracts and two poster abstracts are scheduled to be presented at the American Glaucoma Society (AGS) 26th Annual Meeting, taking place March 3-6, 2016, in Fort Lauderdale, Florida. These presentations provide additional insights into AR-13324, an active ingredient in both of Aerie’s advanced clinical-stage products, RhopressaTM (netarsudil ophthalmic solution) 0.02% and RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%. AR-13324 has recently been granted the USAN name “netarsudil.” The abstracts will be posted on Aerie’s website on March 3, 2016, including all investigator credits.
